Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27768402 | 0.74 | KMT2A (0.50) | MAPTNPC1POLBRAB9AALDH1A1 | |
| SCHEMBL4649312 | 0.74 | NPC1 (0.49) | MAPTNPC1POLBRAB9AEPAS1 | |
| SCHEMBL4555454 | 0.73 | NPC1 (0.74) | MAPTNPC1POLBRAB9AENPP2 | |
| SCHEMBL2731118 | 0.71 | KCNJ1 (0.50) | ENPP2ALDH1A1ADORA3ADORA2AADORA2B | |
| SCHEMBL1708566 | 0.70 | MAPT (0.57) | MAPTNPC1POLBRAB9AEPAS1 | |
| SCHEMBL1525752 | 0.69 | ENPP2 (0.48) | MAPTNPC1POLBRAB9AENPP2 | |
| SCHEMBL11758139 | 0.69 | CA12 (0.51) | — | |
| SCHEMBL1996774 | 0.69 | NPC1 (0.54) | NPC1RAB9AALDH1A1LMNAMEN1 | |
| SCHEMBL2002670 | 0.69 | NPC1 (0.54) | NPC1RAB9AALDH1A1CCNE2CDK4 | |
| SCHEMBL469386 | 0.68 | ALDH1A1 (0.72) | MAPTNPC1RAB9AALDH1A1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1428534-A1 | BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | The Regents of the University of California (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-0960105-B1 | BENZOFURAZAN COMPOUNDS THAT ENHANCE AMPA RECEPTOR ACTIVITY | UNIV CALIFORNIA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6730677-B2 | TREATING MEMORY IMPAIRMENT; ENHANCE EXCITATORY SYNAPTIC ACTIVITY IN ORDER TO RESTORE AN IMBALANCE BETWEEN BRAIN SUBREGIONS, AS IN TREATMENT OF SCHIZOPHRENIA OR SCHIZOPHRENIFORM BEHAVIOR. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-04 | — | — | US | disclosed |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | CORTEX PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-05-09 | — | — | US | disclosed |
| US-6313115-B1 | ALLEVIATE IMPAIRMENT OF MEMORY, OR OTHER COGNITIVE FUNCTIONS CAUSED BY HYPOGLUTAMATERGIC CONDITION OR BY DEFICIENCY IN NUMBER OR STRENGTH OF EXCITATORY SYNAPSES OR IN NUMBER OF AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-06 | — | — | US | disclosed |
| US-6110935-A | A PROMOTER FOR N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTORS, USEFUL FOR SUCH THERAPEUTIC PURPOSES AS FACILITATING THE LEARNING OF BEHAVIORS, TREATING SCHIZOPHRENIA, MEMORY IMPAIRMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | GRIN1, GABRE, GABRG1 | MAPT 3290/4885NPC1 3181/4885POLB 3683/4885 |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | GRIN1, GABRE, GRM1 | MAPT 2417/4885NPC1 3255/4885POLB 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.